SecBot SecBot
8-K ·Filed May 7, 2026

TBPH

Theravance Biopharma, Inc.
MIXED
Impact 5/10
Horizonweeks Processed6mo ago SEC0001104659-26-056733
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The EPS miss may pressure the stock near-term, but the ongoing strategic review and restructuring progress provide upside optionality. Monitor for updates on the sale process and Q2 2026 operating expense reductions.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$17.02
T+0 close · May 7, 2026 · via day close
Latest settled
−0.88%
T+60 · $16.87
Vs SPY
−4.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $17.02entry
  2. T+1 · 6mo ago −0.06%α −0.89% · $17.01
  3. T+5 · 6mo ago −2.06%α −3.56% · $16.67
  4. T+20 · 6mo ago −6.46%α −9.60% · $15.92
  5. T+60 · 4mo ago −0.88%α −4.71% · $16.87
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theravance Biopharma reported Q1 2026 revenue of $17.7M (+15% YoY), slightly above the $17.4M consensus, but GAAP EPS of -$0.10 missed the Street estimate of -$0.05. Net loss improved to -$4.9M from -$13.6M a year ago, and non-GAAP net income turned positive at $0.6M. The company reaffirmed its restructuring and cost-cutting targets, while the strategic review for a potential sale continues.

Key Financial Metrics

EPS
−$0.10
est −$0.05 · -100.0%
Revenue
$17.7M
est $17.4M · +1.7% · +15.0% YoY
Rating
miss

Key Facts

  • Total revenue $17.7M, up 15% YoY from $15.4M, entirely from Viatris collaboration
  • GAAP net loss per share -$0.10 vs. consensus -$0.05 (100% miss)
  • Net loss narrowed to $4.9M from $13.6M in Q1 2025
  • Non-GAAP net income from operations was $0.6M vs. -$8.6M last year
  • Cash & marketable securities $394.7M as of March 31, 2026, no debt
  • Operating expenses (excl. restructuring) down ~20% YoY; restructuring on track for $60-70M annualized cash flow by Q3 2026
  • Strategic Review Committee actively evaluating options including a sale

Financial Impact

EPS miss of $0.05 vs. consensus, revenue beat of $0.3M; net loss improvement of $8.7M YoY is overshadowed by the EPS shortfall

epsrevenuenetIncome

Risk Factors

  • Strategic review may not result in a transaction or may be delayed
  • Failure to achieve $100M TRELEGY milestone if GSK sales fall below $3.5B
  • Execution risk in achieving full restructuring savings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
62% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-056733
Document: tm2613884d1_8k.htm0001104659-26-056733
Document: 0001104659-26-056733-index-headers.html0001104659-26-056733
Document: 0001104659-26-056733-index.html0001104659-26-056733
Document: 0001104659-26-056733.txt0001104659-26-056733
8-K Data (Synthetic)0001104659-26-056733

Track record

12 reports on TBPH

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +2.11% at T+1 after the Mar 3, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry price pending
  2. Oct 5, 20266w ago 15-12G Bearish 7/10 No price data
  3. Sep 25, 20267w ago SC 13D/A Neutral 4/10 Entry $17.04 No price data
  4. Sep 23, 20267w ago 25-NSE Bearish 7/10 Entry $17.05 No price data
  5. Aug 25, 202611w ago DEFA14A Neutral 4/10 Entry $17.03 to $17.03 · 0.00% −0.23% vs SPY
  6. Aug 21, 202612w ago DEFM14A Bullish 7/10 Entry $17.01 to $17.05 ▲ +0.24% +0.76% vs SPY
  7. Aug 11, 202613w ago PREM14A Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.95% vs SPY
  8. Aug 10, 202614w ago 8-K Bullish 7/10 Entry $16.91 to $17.06 ▲ +0.89% +1.80% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 7/10 Entry $17.06 to $16.86 ▼ −1.17% −0.89% vs SPY
  10. Jun 23, 202620w ago 8-K Neutral 2/10 Entry $17.27 to $16.81 ▼ −2.66% −4.60% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026